amifostine + liposomal doxorubicin + oxaliplatin

This is a combination regimen consisting of three agents: - **Amifostine** is a cytoprotective agent and pharmacological antioxidant used to reduce the toxicity of chemotherapy and radiotherapy, particularly by protecting normal tissues from oxidative damage. It is commonly used to prevent renal toxicity associated with platinum-based chemotherapies and to reduce xerostomia in head and neck cancer patients undergoing radiation[6][9][10]. - **Liposomal doxorubicin** is an anthracycline antineoplastic agent encapsulated in liposomes, which alters its distribution profile, reduces cardiotoxicity compared to conventional doxorubicin, and allows for targeted delivery. It acts primarily by intercalating DNA strands, inhibiting topoisomerase II, and generating free radicals that damage cellular components[7]. - **Oxaliplatin** is a platinum-based chemotherapeutic that forms DNA adducts leading to inhibition of DNA replication and transcription. It is widely used in colorectal cancer regimens but also has activity in other solid tumors[4][5]. The combination has been studied as part of hypofractionated accelerated radiochemotherapy regimens for various cancers (e.g., head & neck), where amifostine serves as a protective adjunct against the toxicities induced by liposomal doxorubicin and oxaliplatin[1][2]. Liposomal doxorubicin plus oxaliplatin combinations have demonstrated efficacy especially in relapsed ovarian cancer; adding amifostine may help mitigate neurotoxicity or other side effects without reducing antitumor efficacy[3][5].